Multiple studies have demonstrated that blockade of CD47 enhances phagocytosis and antigen-presenting capabilities of macrophages and neutrophils, thus activating tumor-specific T cells and consequently stimulating adaptive immune responses (4, 11–13). The gene discussed is CD47; the disease is neoplasm.